DK1180159T3 - Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser - Google Patents
Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelserInfo
- Publication number
- DK1180159T3 DK1180159T3 DK00937835T DK00937835T DK1180159T3 DK 1180159 T3 DK1180159 T3 DK 1180159T3 DK 00937835 T DK00937835 T DK 00937835T DK 00937835 T DK00937835 T DK 00937835T DK 1180159 T3 DK1180159 T3 DK 1180159T3
- Authority
- DK
- Denmark
- Prior art keywords
- tnf
- methods
- necrosis factor
- tumor necrosis
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15068899P | 1999-05-28 | 1999-05-28 | |
PCT/US2000/014586 WO2000073481A1 (fr) | 1999-05-28 | 2000-05-26 | Techniques et compositions permettant d'abaisser le niveau de facteur de necrose tumorale (tnf) dans les troubles associes au tnf |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1180159T3 true DK1180159T3 (da) | 2008-11-17 |
Family
ID=22535598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00937835T DK1180159T3 (da) | 1999-05-28 | 2000-05-26 | Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser |
Country Status (11)
Country | Link |
---|---|
US (4) | US6537540B1 (fr) |
EP (1) | EP1180159B1 (fr) |
JP (1) | JP2003501043A (fr) |
AT (1) | ATE407214T1 (fr) |
AU (2) | AU783037B2 (fr) |
CA (1) | CA2374597A1 (fr) |
DE (1) | DE60040147D1 (fr) |
DK (1) | DK1180159T3 (fr) |
ES (1) | ES2312344T3 (fr) |
PT (1) | PT1180159E (fr) |
WO (1) | WO2000073481A1 (fr) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924128B2 (en) * | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US7269457B2 (en) * | 1996-04-30 | 2007-09-11 | Medtronic, Inc. | Method and system for vagal nerve stimulation with multi-site cardiac pacing |
US8036741B2 (en) | 1996-04-30 | 2011-10-11 | Medtronic, Inc. | Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure |
US6449507B1 (en) * | 1996-04-30 | 2002-09-10 | Medtronic, Inc. | Method and system for nerve stimulation prior to and during a medical procedure |
US6904318B2 (en) * | 2000-09-26 | 2005-06-07 | Medtronic, Inc. | Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure |
US6628987B1 (en) * | 2000-09-26 | 2003-09-30 | Medtronic, Inc. | Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia |
US20040199209A1 (en) * | 2003-04-07 | 2004-10-07 | Hill Michael R.S. | Method and system for delivery of vasoactive drugs to the heart prior to and during a medical procedure |
US6479523B1 (en) * | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
US6995006B2 (en) * | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6346415B1 (en) * | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US6537540B1 (en) * | 1999-05-28 | 2003-03-25 | Targeted Genetics Corporation | Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
EP1198271A4 (fr) * | 1999-06-25 | 2009-01-21 | Univ Emory | Dispositifs et methodes de stimulation du nerf vague |
ES2308989T3 (es) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
US6487446B1 (en) * | 2000-09-26 | 2002-11-26 | Medtronic, Inc. | Method and system for spinal cord stimulation prior to and during a medical procedure |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002101012A2 (fr) * | 2001-06-08 | 2002-12-19 | Children's Hospital Research Foundation | Regulation de l'expression transgenique suivant une transduction par aav |
US6845929B2 (en) * | 2002-03-22 | 2005-01-25 | Ali Dolatabadi | High efficiency nozzle for thermal spray of high quality, low oxide content coatings |
JP4863874B2 (ja) * | 2003-09-01 | 2012-01-25 | アカデミッシュ メディッシュ セントラム | 関節リウマチのインビボ遺伝子治療のためのaavベクター |
NZ545656A (en) * | 2003-09-01 | 2009-02-28 | Amc Amsterdam | AAV vectors for in vivo gene therapy of rheumatoid arthritis |
AU2010201278B2 (en) * | 2003-09-01 | 2012-11-15 | Academisch Medisch Centrum | AAV vectors for in vivo gene therapy of rheumatoid arthritis |
AU2004279742A1 (en) * | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
AU2006230419A1 (en) * | 2005-03-31 | 2006-10-05 | Targeted Genetics Corporation | Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
AR059945A1 (es) * | 2005-08-09 | 2008-05-14 | Zymogenetics Inc | Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig |
JP5118037B2 (ja) * | 2005-08-09 | 2013-01-16 | ザイモジェネティクス, インコーポレイテッド | Taci融合分子を用いた異常細胞増殖の処置及び予防のための方法 |
AU2006315758A1 (en) * | 2005-11-10 | 2007-05-24 | Ercole Biotech, Inc. | Splice switching oligomers for TNF superfamily receptors and their use in treatment of disease |
US7785834B2 (en) * | 2005-11-10 | 2010-08-31 | Ercole Biotech, Inc. | Soluble TNF receptors and their use in treatment of disease |
WO2007124148A2 (fr) * | 2006-04-21 | 2007-11-01 | The University Of North Carolina At Chapel Hill | Traitement de troubles du tissu conjonctif |
UA98462C2 (ru) * | 2006-05-15 | 2012-05-25 | Арес Трейдинг С.А. | Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig |
WO2007149115A1 (fr) * | 2006-06-15 | 2007-12-27 | Targeted Genetics Corporation | Procédés de traitement d'articulations cibles dans l'arthrite inflammatoire utilisant des vecteurs aav vectors codant pour un antagoniste du tnf |
US20090264353A1 (en) * | 2007-10-19 | 2009-10-22 | Santaris Pharma A/S | Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease |
EP2423221B1 (fr) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci |
KR20210107137A (ko) | 2008-04-21 | 2021-08-31 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
CA2731769C (fr) | 2008-07-21 | 2013-09-10 | Otonomy, Inc. | Compositions a liberation controlee modulant la structure otique et modulant le systeme immunitaire naturel et procedes de traitement de troubles otiques |
JP5879256B2 (ja) | 2009-05-02 | 2016-03-08 | ジェンザイム・コーポレーション | 神経変性障害のための遺伝子治療 |
US8620425B2 (en) | 2010-04-29 | 2013-12-31 | Medtronic, Inc. | Nerve signal differentiation in cardiac therapy |
US8423134B2 (en) | 2010-04-29 | 2013-04-16 | Medtronic, Inc. | Therapy using perturbation and effect of physiological systems |
US8639327B2 (en) | 2010-04-29 | 2014-01-28 | Medtronic, Inc. | Nerve signal differentiation in cardiac therapy |
US8781583B2 (en) | 2011-01-19 | 2014-07-15 | Medtronic, Inc. | Vagal stimulation |
US8781582B2 (en) | 2011-01-19 | 2014-07-15 | Medtronic, Inc. | Vagal stimulation |
US8718763B2 (en) | 2011-01-19 | 2014-05-06 | Medtronic, Inc. | Vagal stimulation |
US8725259B2 (en) | 2011-01-19 | 2014-05-13 | Medtronic, Inc. | Vagal stimulation |
US8706223B2 (en) | 2011-01-19 | 2014-04-22 | Medtronic, Inc. | Preventative vagal stimulation |
CN105636614A (zh) | 2013-09-09 | 2016-06-01 | 菲格内有限责任公司 | 用于软骨细胞或软骨型细胞再生的基因治疗 |
WO2015077717A1 (fr) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn |
WO2015085147A1 (fr) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Typage de gènes polymorphes et détection de changements somatiques à l'aide de données de séquençage |
KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
WO2016100977A1 (fr) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Procédés pour le profilage du répertoire de récepteurs de cellules t |
WO2016145150A2 (fr) | 2015-03-11 | 2016-09-15 | The Broad Institute Inc. | Traitement sélectif de cancer dépendant de prmt5 |
MX2017014700A (es) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
TWI750122B (zh) | 2015-06-09 | 2021-12-21 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
WO2017184590A1 (fr) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Prédiction améliorée d'épitope hla |
CA3029281A1 (fr) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Formulations otiques a base de triglycerides et leurs utilisations |
WO2018035451A1 (fr) | 2016-08-19 | 2018-02-22 | Calimmune, Inc. | Méthodes et compositions pour le traitement d'affections à l'aide d'un virus adéno-associé recombinant auto-complémentaire |
WO2018106956A2 (fr) | 2016-12-07 | 2018-06-14 | University Of Florida Research Foundation, Incorporated | Adnc d'il-1ra |
WO2018140391A1 (fr) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions et procédés de détection d'un variant mutant d'un polynucléotide |
CN116693695A (zh) | 2017-02-12 | 2023-09-05 | 百欧恩泰美国公司 | 基于hla的方法和组合物及其用途 |
US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
WO2020072700A1 (fr) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Lignées d'allèles uniques d'alh |
WO2020131586A2 (fr) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Méthodes d'identification de néo-antigènes |
EP3899954A4 (fr) | 2018-12-21 | 2022-09-14 | BioNTech US Inc. | Procédé et systèmes de prédiction d'épitopes spécifiques des hla de classe ii et caractérisation de lymphocytes t cd4+ |
EP4259206A2 (fr) | 2020-12-14 | 2023-10-18 | BioNTech US Inc. | Antigènes spécifiques de tissu pour une immunothérapie anticancéreuse |
WO2024015892A1 (fr) | 2022-07-13 | 2024-01-18 | The Broad Institute, Inc. | Procédés et systèmes faisant intervenir l'immunopeptidome hla-ii pour la découverte d'antigènes |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
WO1992011359A1 (fr) | 1990-12-20 | 1992-07-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene recepteur tronque d'interleukine-1 utilise pour le traitement de l'arthrite |
US6159464A (en) * | 1990-12-20 | 2000-12-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints |
US6413511B1 (en) * | 1990-12-20 | 2002-07-02 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide |
US5858355A (en) | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
US5792751A (en) | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
CA2123593C (fr) | 1992-09-15 | 2000-03-14 | Craig A. Smith | Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale |
US5962316A (en) * | 1992-10-16 | 1999-10-05 | Cold Spring Harbor Laboratory | Cell-cycle regulatory proteins, and uses related thereto |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
JPH08511507A (ja) | 1993-03-08 | 1996-12-03 | ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 哺乳動物宿主の結合組織を処置するための遺伝子導入 |
FR2711523B1 (fr) * | 1993-10-26 | 1996-02-16 | Transgene Sa | Procédé de préparation d'un aérosol viral. |
DK0733103T3 (da) | 1993-11-09 | 2004-07-12 | Univ Johns Hopkins | Fremstilling af höje titre af rekombinante AAV vektorer |
WO1995013392A1 (fr) | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Lignees cellulaires stables aptes a exprimer le gene de replication du virus adeno-associe |
CA2155929A1 (fr) | 1993-12-14 | 1995-06-22 | Christopher H. Evans | Traitement systemique par genes des affections des tissus conjonctifs |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
JPH10511264A (ja) | 1994-12-06 | 1998-11-04 | ターゲティッド ジェネティックス コーポレイション | 高力価組換えaavベクターの生成のためのパッケージング細胞株 |
US5843742A (en) | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
US5962424A (en) * | 1995-02-21 | 1999-10-05 | Arch Development Corporation | Methods and compositions for targeting selectins |
US6656466B1 (en) * | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
US5858351A (en) | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
US5846528A (en) | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
US5672508A (en) * | 1996-01-23 | 1997-09-30 | Mitotix, Inc. | Inhibitors of cell-cycle progression, and uses related thereto |
CA2247099A1 (fr) | 1996-03-04 | 1997-09-12 | Targeted Genetics Corporation | Procede de transduction de cellules dans des vaisseaux sanguins a l'aide de vecteurs de virus adeno-associes (vaa) recombinants |
US5780447A (en) | 1996-06-14 | 1998-07-14 | St. Jude Children's Research Hospital | Recombinant adeno-associated viral vectors |
CA2273850A1 (fr) * | 1996-12-06 | 1998-06-11 | Amgen Inc. | Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf |
AU5603998A (en) | 1996-12-18 | 1998-07-15 | Targeted Genetics Corporation | Recombinase-activatable AAV packaging cassettes for use in the production of AV vectors |
US6541258B2 (en) * | 1996-12-18 | 2003-04-01 | Targeted Genetics Corporation | AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors |
RU2198683C2 (ru) | 1997-02-28 | 2003-02-20 | Берингер Ингельхайм Фармасьютикельс, Инк. | Саморегулируемый апоптоз воспалительных клеток с помощью генной терапии |
US6281200B1 (en) * | 1997-08-15 | 2001-08-28 | Advanced Research & Technology Institute | Functional characterization of the C-C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2 |
AU9036198A (en) * | 1997-08-26 | 1999-03-16 | Ariad Gene Therapeutics, Inc. | Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain |
CA2995542A1 (fr) | 1997-09-05 | 1999-03-11 | Genzyme Corporation | Procedes de generation de preparations de vecteurs de aav recombinants dont le titre est eleve et qui sont exemptes de virus assistant |
JP2001520051A (ja) | 1997-10-21 | 2001-10-30 | ターゲテッド ジェネティックス コーポレイション | 組換えaavベクターの産生のための増幅可能アデノ随伴ウイルス(aav)パッケージングカセット |
JP2001520047A (ja) | 1997-10-21 | 2001-10-30 | ターゲテッド ジェネティックス コーポレイション | 組換えaavベクターと共に使用するための転写活性化された逆方向末端反復(itr) |
US6346415B1 (en) * | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
ES2541540T3 (es) | 1998-09-04 | 2015-07-21 | Genzyme Corporation | Métodos para generar preparados exentos de helper de alto título de vectores de AAV recombinantes liberados |
US6537540B1 (en) * | 1999-05-28 | 2003-03-25 | Targeted Genetics Corporation | Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
US6579522B1 (en) * | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
-
2000
- 2000-05-26 US US09/579,845 patent/US6537540B1/en not_active Expired - Fee Related
- 2000-05-26 AU AU52958/00A patent/AU783037B2/en not_active Ceased
- 2000-05-26 DE DE60040147T patent/DE60040147D1/de not_active Expired - Fee Related
- 2000-05-26 DK DK00937835T patent/DK1180159T3/da active
- 2000-05-26 WO PCT/US2000/014586 patent/WO2000073481A1/fr active IP Right Grant
- 2000-05-26 ES ES00937835T patent/ES2312344T3/es not_active Expired - Lifetime
- 2000-05-26 CA CA002374597A patent/CA2374597A1/fr not_active Abandoned
- 2000-05-26 JP JP2001500793A patent/JP2003501043A/ja active Pending
- 2000-05-26 EP EP00937835A patent/EP1180159B1/fr not_active Expired - Lifetime
- 2000-05-26 PT PT00937835T patent/PT1180159E/pt unknown
- 2000-05-26 AT AT00937835T patent/ATE407214T1/de not_active IP Right Cessation
-
2002
- 2002-12-06 US US10/314,033 patent/US20030113295A1/en not_active Abandoned
- 2002-12-06 US US10/313,852 patent/US20030103942A1/en not_active Abandoned
-
2005
- 2005-12-14 AU AU2005244527A patent/AU2005244527C1/en not_active Ceased
-
2006
- 2006-07-17 US US11/488,520 patent/US20070128177A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2312344T3 (es) | 2009-03-01 |
PT1180159E (pt) | 2008-12-05 |
US20070128177A1 (en) | 2007-06-07 |
EP1180159A1 (fr) | 2002-02-20 |
AU2005244527C1 (en) | 2009-02-05 |
US6537540B1 (en) | 2003-03-25 |
AU2005244527A1 (en) | 2006-01-19 |
WO2000073481A1 (fr) | 2000-12-07 |
EP1180159B1 (fr) | 2008-09-03 |
CA2374597A1 (fr) | 2000-12-07 |
US20030103942A1 (en) | 2003-06-05 |
US20030113295A1 (en) | 2003-06-19 |
JP2003501043A (ja) | 2003-01-14 |
AU2005244527B2 (en) | 2008-09-18 |
DE60040147D1 (de) | 2008-10-16 |
AU783037B2 (en) | 2005-09-15 |
AU5295800A (en) | 2000-12-18 |
ATE407214T1 (de) | 2008-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1180159T3 (da) | Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser | |
EE200100006A (et) | Bifenüülsulfoonamiidid kui duaalse angiotensiin-endoteliini retseptori antagonistid | |
NO20053556L (no) | Polymerkonjugater av interferon-beta med forbedret biologisk potens. | |
DE69835518D1 (de) | Imidazolyl-cyclische acetale | |
DK1966238T3 (da) | INTERLEUKIN-12P40-varianter med forbedret stabilitet | |
IL229738A0 (en) | Methods and preparations for increasing the expression of fusion proteins of a member of the tumor necrosis factor receptor (TNF)-ig fc family | |
ATE420644T1 (de) | Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1) | |
NO20053555D0 (no) | Polymerkonjugater av cytokiner, chemokiner, vekstfaktorer, polypeptidhormoner og antagonister derav med preservert reseptorbindingsaktivitet. | |
ATE323088T1 (de) | Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten | |
DK1011704T3 (da) | Tumornekrose-faktor-receptor-afledte peptid-analiger | |
YU50001A (sh) | 4-(heterociklilsulfonamido)-5-metoksi-6-(2-metoksi-fenoksi) -2-fenil-ili piridil-pirimidini kao antagonisti endotelinskih receptora | |
DK0526905T3 (da) | Multimerer af TNF-receptorers oplöselige former, deres fremstilling og farmaceutiske præparater indeholdende dem | |
ATE321855T1 (de) | Tumor-nekrose-faktor rezeptor 5 | |
EA200000310A1 (ru) | April - новый белок, воздействующий на рост | |
DK1533311T3 (da) | Sulfonamider og derivater deraf, der modulerer aktiviteten af endothelin | |
WO2001064856A3 (fr) | Regulateurs du recepteur de type 1 de facteur de necrose des tumeurs et elimination d'autres recepteurs de cytokine | |
ATE541041T1 (de) | Produktion von rekombinantem aav mit hohem titer | |
EA200201019A1 (ru) | Антагонисты рецептора il-8 | |
IT1311665B1 (it) | Dispositivo di regolazione, particolarmente per un attacco dasnowboard. | |
WO2006105344A3 (fr) | Procedes d'abaissement de niveau de facteur tnf dans les troubles associes a ce facteur | |
DK1537203T3 (da) | ANVENDELSE AF DENDRITISKE CELLER (DC'er) DER UDTRYKKER INTERLEUKIN 12 (IL-12) | |
DK1196188T3 (da) | VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser | |
EP1495056A4 (fr) | Isomeres de disulfure d'anticorps, utilisation de ces isomeres et procedes d'analyse de ces isomeres | |
DK1308444T3 (da) | Substitueret 2(2,6 dioxo-3-fluorpiperidin-3-yl)-isoindoliner og deres anvendelse til reduktion af TNFalfa-niveau'er | |
DK1664315T3 (da) | AAV-vektorer til in vivo genterapi af rheumatoid arthritis |